Verona Pharma plc
VRNA
$105.27
$0.070.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 173.05% | 51.76% | 21.26% | 39.35% | -174.62% |
| Total Depreciation and Amortization | -0.68% | 13.90% | -2.63% | -1.48% | 2.66% |
| Total Amortization of Deferred Charges | 5.81% | 24.10% | -32.18% | 282.76% | 147.56% |
| Total Other Non-Cash Items | -13.70% | 104.75% | 292.41% | -151.51% | 321.55% |
| Change in Net Operating Assets | 54.45% | -137.02% | -37.50% | -131.81% | 367.66% |
| Cash from Operations | 364.35% | 59.91% | 53.98% | -266.36% | -25.66% |
| Capital Expenditure | 100.00% | 0.00% | -- | 100.00% | -81.25% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | 0.00% | -- | 100.00% | -81.25% |
| Total Debt Issued | -100.00% | -- | -- | -100.00% | -- |
| Total Debt Repaid | -- | -- | -- | 100.00% | -- |
| Issuance of Common Stock | -4.30% | -94.75% | 2,583.21% | -- | -100.00% |
| Repurchase of Common Stock | 100.00% | -2,579.05% | 30.60% | -317.04% | 58.80% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -104.70% | 27,039.84% |
| Cash from Financing | -63.27% | -85.71% | 1,428.59% | -104.25% | 5,442.04% |
| Foreign Exchange rate Adjustments | 269.36% | 127.78% | -190.36% | 7,293.75% | 111.35% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,107.54% | -97.40% | 192.94% | -145.79% | 986.42% |